PMID- 34533051
OWN - NLM
STAT- MEDLINE
DCOM- 20220321
LR  - 20220321
IS  - 1752-0371 (Electronic)
IS  - 1752-0363 (Linking)
VI  - 15
IP  - 15
DP  - 2021 Oct
TI  - Vitamin D level predicts angiographic no-reflow phenomenon after percutaneous 
      coronary intervention in patients with ST segment elevation myocardial 
      infarction.
PG  - 1357-1366
LID - 10.2217/bmm-2020-0689 [doi]
AB  - Aim: No-reflow phenomenon (NRP) is an undesirable result of coronary 
      interventions, and usually occurred during the primary percutaneous coronary 
      intervention (PPCI). On the other hand, there is growing evidence of 
      epidemiological studies suggest that serum 25 hydroxy-vitamin D (25(OH)D3) level 
      is significantly associated with cardiovascular mortality and morbidity. 
      Objective: To investigate whether there is a relationship between admission serum 
      25(OH)D3 levels and NRP in patients with ST elevation myocardial infarction 
      (STEMI). Methods: This study consisted of 496 consecutive acute STEMI patients 
      who underwent PPCI. After the restoration of antegrade flow, the patients were 
      divided into the normal flow and no-reflow groups. No-reflow defined as; 
      thrombosis in myocardial infarction (TIMI) flow grade </=2, or a TIMI flow 
      grade = 3 with a myocardial perfusion grade </=1. Results: Angiographic no-reflow 
      occurred 18.2% of all study patients. Serum 25(OH)D3 levels were significantly 
      lower when compared with the normal flow group (14.6 +/- 7.3 vs 
      22.6 +/- 9.6 ng/ml; p < 0.001). 25(OH)D3 level was significantly negatively 
      correlated with Neutrophil/lymphocyte (N/L) ratio. In multivariate analysis, 
      25(OH)D3 level on admission (OR: 0.738; 95% CI: 0.584-0.878; p = 0.001) was found 
      an independent predictor of NRP together with N/L ratio, N-Terminal-proBNP, 
      balloon pre dilatation and syntax score I. On receiver operating curve analysis 
      (ROC), the cut-off value of admission 25(OH)D3 level was 10.5 ng/ml for the 
      prediction of NRP with a sensitivity of 93% and specificity of 68%. The area 
      under the ROC curve (AUC) was 0.772 (95% CI: 0.697-0.846; p < 0.001). Conclusion: 
      We have shown that lower 25(OH)D3 level on admission is associated with higher 
      NRP frequency and may be used as a predictor for NRP in STEMI patients undergoing 
      PPCI.
FAU - Sen, Omer
AU  - Sen O
AUID- ORCID: 0000-0002-6782-2899
AD  - Department of Cardiology, Adana City Education & Research Hospital, University of 
      Health Sciences, Yuregir, Adana, 01358, Turkey.
FAU - Sen, Sidika B
AU  - Sen SB
AUID- ORCID: 0000-0003-1084-4226
AD  - Department of Physiotherapy & Rehabilitation, Adana City Education & Research 
      Hospital, University of Health Sciences, Yuregir, Adana, 01358, Turkey.
FAU - Topuz, Ayse N
AU  - Topuz AN
AUID- ORCID: 0000-0003-0970-228X
AD  - Department of Family Medicine, Cukurova University Medicine Faculty, Adana, 
      01410, Turkey.
FAU - Topuz, Mustafa
AU  - Topuz M
AUID- ORCID: 0000-0002-6323-212X
AD  - Department of Cardiology, Adana City Education & Research Hospital, University of 
      Health Sciences, Yuregir, Adana, 01358, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20210917
PL  - England
TA  - Biomark Med
JT  - Biomarkers in medicine
JID - 101312535
RN  - 0 (Biomarkers)
RN  - 1406-16-2 (Vitamin D)
SB  - IM
MH  - Aged
MH  - Biomarkers/*blood
MH  - Coronary Angiography/*methods
MH  - Female
MH  - Humans
MH  - Leukocyte Count
MH  - Lymphocytes/pathology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neutrophils/pathology
MH  - No-Reflow Phenomenon/*blood/diagnosis
MH  - Percutaneous Coronary Intervention/*methods
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - ROC Curve
MH  - ST Elevation Myocardial Infarction/*blood/diagnosis/surgery
MH  - Vitamin D/*blood
OTO - NOTNLM
OT  - STEMI
OT  - neutrophil/lymphocyte ratio
OT  - no-reflow
OT  - reperfusion injury
OT  - vitamin D
EDAT- 2021/09/18 06:00
MHDA- 2022/03/22 06:00
CRDT- 2021/09/17 08:38
PHST- 2021/09/18 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
PHST- 2021/09/17 08:38 [entrez]
AID - 10.2217/bmm-2020-0689 [doi]
PST - ppublish
SO  - Biomark Med. 2021 Oct;15(15):1357-1366. doi: 10.2217/bmm-2020-0689. Epub 2021 Sep 
      17.